Antiphospholipid Syndrome News

SAN DIEGO — Primary prevention remains the biggest treatment challenge in antiphospholipid syndrome, according to a speaker at the Congress of Clinical Rheumatology West.

Sufficient disease control prior to conception can reduce the risk for pregnancy complications in patients with rheumatic conditions, according to a press release announcing data published in Rheumatic Disease Clinics of North America.

Reducing the risk for thrombotic events in patients with antiphospholipid syndrome means striking the proper balance of monitoring and anticoagulation therapy, according to Richard A. Furie, MD, of Northwell Health in New York.

Peer-reviewed papers on pediatric antiphospholipid syndrome do not appear very often.

March is Autoimmune Awareness Month, and rheumatology organizations have been using their reach and influence on social media sites to spread the word and help patients with autoimmune diseases find community.

One out of three registered randomized controlled trials on connective tissue diseases are never completed or published, representing a “waste of energy or resources” that may skew meta-analyses, according to researchers.

Heart rate monitoring may be a crucial means of detecting rhythm abnormalities in the fetuses of pregnant individuals who are positive for anti-Ro/SSA antibodies, according to data presented at ACR Convergence 2021.

Healio announced the launch of Rheum and Boards, a quiz-based, online learning resource for rheumatologists, according to a Healio press release.

Patients with rheumatic diseases who were pregnant at the time of developing COVID-19 demonstrated favorable pregnancy and infection outcomes, according to data published in The Journal of Rheumatology.

Persistent low-to-moderate thrombocytopenia can identify patients with antiphospholipid syndrome who are at high risk for thrombosis, and is linked to poor long-term survival, according to data published in Rheumatology.